Strategic Partnerships BioSkryb has a history of active collaborations with industry players and research consortia, including partnerships with Human Cell Atlas, Tecan, and regional distributors. This indicates a receptive ecosystem for channel and co-development opportunities to expand in multiomic workflows and high-throughput sequencing services.

Early Access Programs The launch of ResolveSEQ LongRead Early Access and the associated press presence signal opportunities to engage KOLs and early adopters, offering a pathway to trial, feedback, and case studies that can accelerate broader procurement with pharma, academic, and clinical labs.

High Throughput Demand Recent collaborations focus on scalable library preparation and single-cell workflows, suggesting strong demand from labs scaling single-cell sequencing. This aligns with targets in core facilities, CROs, and contract service providers seeking automation-ready, time-efficient multiomic solutions.

Geographic & Channel Growth Distribution partnerships in Southeast Asia and ongoing US-based initiatives indicate a multi-region go-to-market approach. This creates cross-sell opportunities via CSPs and regional distributors to expand presence in emerging markets with compatible service providers.

Financially Favorable Scale With revenue in the lower tens of millions and venture-backed funding, BioSkryb appears positioned to invest in sales expansion, field enablement, and strategic alliances to capture share from mid-size to large players in the multiomic space.